Latanoprostene Bunod

Class: Prostaglandin Analogs
Chemical Name: 4-(Nitrooxy) butyl (5Z)-7-{(1R,2R,3R,5S)-3,5- dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl] cyclopentyl}hept-5-enoate
Molecular Formula: C₂₇H₄₁NO₈
CAS Number: 860005-21-6
Brands: Vyzulta

Medically reviewed by Drugs.com on Nov 2, 2020. Written by ASHP.

Introduction

Ocular hypotensive agent; synthetic analog of prostaglandin F_2α (PGF_2α).

Uses for Latanoprostene Bunod

Ocular Hypertension and Glaucoma

Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

Once-daily latanoprostene bunod 0.024% ophthalmic solution appears to be more effective than or at least as effective as twice-daily timolol 0.5% ophthalmic solution in reducing IOP in adults with open-angle glaucoma or ocular hypertension.

When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost). With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostaglandin analogs; 20–25% with topical β-adrenergic blocking agents, α-adrenergic agonists, or miotic (parasympathomimetic) agents; 20–30% with oral carbonic anhydrase inhibitors; 18% with topical rho kinase inhibitors; and 15–20% with topical carbonic anhydrase inhibitors.

A prostaglandin analog frequently is considered for initial therapy in the absence of other considerations (e.g., contraindications, cost considerations, intolerance, adverse effects, patient refusal) because of relatively greater activity, once-daily administration, and low frequency of systemic adverse effects; however, ocular adverse effects can occur.

Goal is to maintain an IOP at which visual field loss is unlikely to substantially reduce quality of life during the patient's lifetime.

Reduction of pretreatment IOP by ≥25% shown to slow progression of primary open-angle glaucoma. Set an initial target IOP (based on extent of optic nerve damage and/or visual field loss, baseline IOP at which damage occurred, rate of progression, life expectancy, and other considerations) and reduce IOP toward this goal. Adjust target IOP up or down as needed over course of disease.

Combination therapy with drugs from different therapeutic classes often required to control IOP.

Latanoprostene Bunod Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the affected eye(s).

Avoid contaminating solution container. (See Bacterial Keratitis under Cautions.)

Remove contact lenses prior to administration of each dose; may reinsert contact lenses 15 minutes after the dose. (See Use with Contact Lenses under Cautions.)

If more than one topical ophthalmic drug used, administer the drugs at least 5 minutes apart.

Dosage

Adults

Ocular Hypertension and Glaucoma

Ophthalmic

Latanoprostene bunod 0.024% ophthalmic solution: One drop into conjunctival sac of affected eye(s) once daily in the evening.

More...